echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Lancet subjournal: Long-distance ischemic adaptation of Ji Xunming's team of Capital Medical University has a significant protective effect on stroke

    Lancet subjournal: Long-distance ischemic adaptation of Ji Xunming's team of Capital Medical University has a significant protective effect on stroke

    • Last Update: 2022-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Stroke is the first fatal and disabling disease
    in China.
    China adopts the same prevention and control guidelines as European and American countries, but China's prevention and control effect is not satisfactory, and the incidence and recurrence rate still rank first in the world, causing a heavy burden
    on society, economy and families.
    Stroke in European and American populations is dominated by extracranial atherosclerosis, while Chinese group is dominated by intracranial atherosclerosis (China
    46% vs Europe and the United States 9%)
    .

    Intracranial atherosclerotic stenosis (ICAS) is one of the most common causes of stroke worldwide, and currently recommended treatments are associated with
    a high risk of stroke recurrence.

    On October 27, 2022, led by the team of Professor Ji Xunming of Capital Medical University, 84 hospitals in China cooperated in Lancet Neurology ( IF=60) published online titled “Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis (the RICA trial): a multicentre, randomised, double-blind sham-controlled trial in China", which found that long-range ischemic adaptation reduced the recurrence rate of stroke by 24% and the incidence of cardiovascular and cerebrovascular diseases by 30%.

    This study provides high-level medical evidence
    for the adaptation of distant ischemia for symptomatic intracranial atherosclerotic stenosis.

    Extracranial atherosclerotic stenosis can be treated with surgery or stents, while clinical studies of intracranial atherosclerotic stenosis surgery or stent have not yielded positive results
    .
    Despite intensive drug therapy, the risk of stroke recurrence in age is as high as
    20%.

    To assess the effectiveness of chronic remote ischemia regulation in preventing ischemic events in symptomatic ICAS patients, the study conducted the RICA trial, a multicenter, randomized, double-blind, sham controlled trial
    conducted in 84 stroke centers in China.
    Patients aged
    40-80 years with angiography confirmed 50-99% stenosis of the intracranial aortic arteries leading to ischemic stroke or transient ischemic attack, through computer-generated random coding, through an interactive network system, random (1:1).
    Assigned to remote ischemic regulation or pseudo-remote ischemic regulation, once a day for 12 months, after which it is
    performed voluntarily.
    All investigators and patients were informed of treatment allocation
    .
    The primary efficacy endpoint was the time to first occurrence of non-fatal or fatal ischemic stroke, and survival was analysed using the
    Kaplan-Meier method
    .

    From October 28, 2015 to February 28, 2019 During this day, 3033 eligible patients were enrolled and randomly assigned to the remote ischemic conditioning group (n=1517; experimental group) or pseudodistal ischemic conditioning (n=1516; Control group).

    The median follow-up was
    3.
    5
    years (IQR 2.
    7 to 4.
    4).

    The study found that non-fatal or fatal ischemic stroke occurred
    in 257 cases (16.
    9%) in the experimental group and 288 (19.
    0%)
    in the control group
    。 There was no difference in the distribution of survival between non-fatal and fatal ischaemic stroke when it first occurred
    (hazard ratio 0.
    87, 95% CI 0.
    74 to 1·03; p = 0·12)

    In addition, 79 (5.
    2%) patients died in the trial group and 84 (5.
    5%)
    patients in the control group died from any cause (hazard ratio 0.
    93,95% CI 0.
    68 - 1.
    27; p = 0·65)

    。 No serious adverse events
    related to the intervention were observed.
    This suggests that
    long-term distant ischemic adaptation can reduce the incidence
    of cardiovascular and cerebrovascular diseases in patients with ischemic stroke or TIA due to symptomatic intracranial atherosclerotic stenosis.

    Survival curves for primary endpoints (ischemic stroke) and composite endpoints (stroke, TIA, myocardial infarction) (figure from Lancet Neurology).

    Taken together, the study showed no difference
    in the risk of ischemic stroke between remote ischemic conditioning and pseudo-ischemic conditioning in patients with symptomatic ICAS.
    The benefits of remote ischemic regulation may be diluted
    by poor adherence.
    Future studies of remote ischemic conditioning in this population should address patient adherence challenges and evaluate long-term treatment
    .

    Original link:

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.